Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...